David A. Siegel Eledon Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.14 - $1.66 $11,285 - $16,434	-9,900 Reduced 43.04%	13,100 $17,000
Q2 2023 Aug 14, 2023	SELL	$1.34 - $2.85 $2,814 - $5,985	-2,100 Reduced 8.37%	23,000 $31,000
Q1 2023 May 15, 2023	SELL	$2.0 - $3.46 $1,000 - $1,730	-500 Reduced 1.95%	25,100 $59,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $2.75 $36,022 - $45,650	-16,600 Reduced 39.34%	25,600 $58,000
Q3 2022 Nov 14, 2022	SELL	$2.45 - $3.88 $6,860 - $10,864	-2,800 Reduced 6.22%	42,200 $116,000
Q2 2022 Aug 15, 2022	SELL	$2.34 - $3.96 $91,285 - $154,483	-39,011 Reduced 46.44%	45,000 $110,000
Q1 2022 May 16, 2022	SELL	$3.06 - $4.89 $133,382 - $213,150	-43,589 Reduced 34.16%	84,011 $331,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $6.07 $47,033 - $71,019	11,700 Added 10.09%	127,600 $563,000
Q3 2021 Nov 15, 2021	BUY	$5.94 - $8.46 $223,344 - $318,096	37,600 Added 48.02%	115,900 $716,000
Q2 2021 Aug 16, 2021	BUY	$7.62 - $11.75 $458,724 - $707,350	60,200 Added 332.6%	78,300 $619,000
Q1 2021 May 17, 2021	BUY	$9.85 - $19.22 $178,285 - $347,882	18,100 New	18,100 $194,000

18.4M

Ticker ELDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,756,800
Market Cap $60M
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.